Levi & Korsinsky, LLP is investigating Impax Laboratories, Inc. (“Impax” or the “Company”) (Nasdaq:IPXL) in connection with possible breaches of federal securities laws. To get more information, click here: http://zlk.9nl.com/impaxlabs. There is no cost or obligation to you. On July 29, 2014, Impax issued a press release announcing the receipt of a Form 483 from the U.S. Food and Drug Administration (“FDA”) related to the FDA’s inspection of the Company’s Taiwan manufacturing facility; the Form cited ten inspectional observations. If you own common stock in Impax and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/impaxlabs. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
More from Press Releases
NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling
The Supreme Court rules that previous congressional action forbidding states from legalizing sports betting was unconstitutional.
Walmart CEO: 'We Are Transforming Globally' With Flipkart
On its investor call on Wednesday morning, Walmart discusses the Flipkart deal.
March 24 Full-Day Course Offering: Professional Approach to Trading SPX
OptionsProfits, the CBOE, and Option Pit are hosting a class on March 24 that covers a wide variety of methods to trade the S&P 500.